Search company, investor...

Cytoguide ApS

cytoguide.dk

Stage

Other Investors | Alive

About Cytoguide ApS

CytoGuide focuses on the development of two-component drugs that has the potential to maximise the effectiveness of a well-known Rheumatoid Arthritis treatment while drastically minimising its side effects.

Headquarters Location

INCUBA Science Park Gustav Wieds Vej 10

DK 8000,

Denmark

458-620-5294

Missing: Cytoguide ApS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cytoguide ApS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cytoguide ApS Patents

Cytoguide ApS has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/1/2016

Glucocorticoids, Pregnanes, Fluoroarenes, Diketones, Hepatotoxins

Application

Application Date

12/1/2016

Grant Date

Title

Related Topics

Glucocorticoids, Pregnanes, Fluoroarenes, Diketones, Hepatotoxins

Status

Application

Cytoguide ApS Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cytoguide ApS Rank

Cytoguide ApS Frequently Asked Questions (FAQ)

  • What is Cytoguide ApS's latest funding round?

    Cytoguide ApS's latest funding round is Other Investors.

  • Who are the investors of Cytoguide ApS?

    Investors of Cytoguide ApS include Novo Holdings.

  • Who are Cytoguide ApS's competitors?

    Competitors of Cytoguide ApS include Rigel Pharmaceuticals, Actinobac Biomed, Acetylon Pharmaceuticals, Envoy Therapeutics, Javelin Pharmaceuticals and 10 more.

Compare Cytoguide ApS to Competitors

L
Labopharm

Labopharm is an international, specialty pharmaceutical company that develops improved formulations of currently marketed drugs using the Company's advanced, controlled-release technologies. Labopharm's strategy is to leverage these technologies to develop and commercialize new formulations of existing products that address the market's preference for drugs that offer simplified dosing regimens, improved efficacy or a reduced side effect profile.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

C
Chemopreventia

Chemopreventia focuses on the development of cancer preventive drugs and works on the mechanism of action of retinoids and other chemopreventive agents in the control of epithelial cancers. The company also focuses on the protein receptors that mediate the action of chemopreventive agents.

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

V
Virdante Pharmaceuticals

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. The company's products incorporate a proprietary sialic switch technology to improve the anti-inflammatory properties of antibodies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.